Bioxytran

Bioxytran R&D per Employee

The R&D Spending per Employee of Bioxytran (BIXT) as of Oct 10, 2026 is 227,000.00 USD. In the previous year, R&D Spending per Employee was 56,168.50 USD — a change of 304.14% (higher).

R&D per Employee

227,000.00USD

YoY

304.14%

Last updated:

R&D Spending per Employee of Bioxytran is 2025 227,000.00 USD. R&D Spending per Employee of Bioxytran was 2024 56,168.50 USD. It decreases by 304.14% higher compared to the previous year.

The Bioxytran R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2020
272,259.50 USD
Jan 1, 2021
1.01 M USD
Jan 1, 2022
638,884.00 USD
Jan 1, 2023
574,604.50 USD
Jan 1, 2024
56,168.50 USD
Jan 1, 2025
227,000.00 USD
The Bioxytran R&D per Employee history
YEARR&D per EmployeeYoY
227,000.00USD+304.14%
56,168.50USD-90.22%
574,604.50USD-10.06%
638,884.00USD-36.55%
1.01 MUSD+269.82%
272,259.50USD—
Access this data via the Eulerpool API

Bioxytran Stock analysis

What does Bioxytran do? Bioxytran Inc. is a US-based company specialized in the development of medical therapies based on the use of oxygen transport molecules. The company's patented platform technology focuses on the development of new innovative therapies for treating central nervous system disorders, cardiovascular diseases, and cancer treatment. The company was founded in 2014 by a group of scientists and entrepreneurs aiming to create a transformative medical product that improves oxygen transport in the body and enables the treatment of severe diseases. Bioxytran's platform is based on the use of perfluorocarbon compounds (PFCs) that have a strong affinity for oxygen and can bind and transport it in the blood. The company's business model is centered on the development and commercialization of new therapies to treat diseases such as stroke, heart attack, cancer, and even COVID-19. By improving oxygen transport in the body, Bioxytran aims to enhance the effectiveness of medical treatments and create new therapeutic possibilities. The company's focus areas include stroke treatment, where they have developed a technology that allows direct oxygen transport to the affected brain tissue, minimizing neural damage and enabling faster recovery. They have also developed a new type of heart attack treatment that aims to improve blood flow and eliminate oxygen deficiency in the heart, as well as another therapy option for patients suffering from acute heart attacks. In the field of cancer treatment, Bioxytran has a promising therapy in the pipeline based on PFCs that can selectively target cancer cells, potentially making chemotherapy more effective and patient-friendly. Overall, Bioxytran's goal is to develop medical therapies that have the potential to revolutionize the treatment of severe diseases. They offer a range of products and approaches that have the potential to improve the lives of many patients. In summary, Bioxytran Inc. is an emerging company in the field of medical therapies, driven by innovation and technological expertise. Their focus on developing high-potential products that improve oxygen transport in the body facilitates the treatment of severe diseases. With their various divisions and products, Bioxytran is able to address a broad spectrum of medical needs. Bioxytran is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioxytran stock

R&D Spending per Employee of Bioxytran is 227,000.00 USD in 2025.

R&D Spending per Employee of Bioxytran changed from 56,168.50 USD to 227,000.00 USD, representing a 304.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Bioxytran since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Bioxytran historically and in real time.

Access this data via the Eulerpool API

Workforce — Bioxytran

All Key Metrics — Bioxytran